Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 169

Results For "Pharma"

4734 News Found

BD announces $110 million investment in Nebraska to expand prefillable syringe production
News | January 15, 2026

BD announces $110 million investment in Nebraska to expand prefillable syringe production

The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products


Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids
R&D | January 15, 2026

Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids

The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms


Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM
Clinical Trials | January 14, 2026

Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM

The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo


Camurus’ Oclaiz NDA resubmission accepted by FDA
Drug Approval | January 14, 2026

Camurus’ Oclaiz NDA resubmission accepted by FDA

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026


Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents
News | January 14, 2026

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics


AbbVie strikes deal with Trump administration on drug prices, US investment
News | January 13, 2026

AbbVie strikes deal with Trump administration on drug prices, US investment

AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing


Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer
Clinical Trials | January 12, 2026

Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer

The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population